TP方案与NP方案治疗晚期乳腺癌的临床观察

目的观察TP方案与NP方案治疗晚期乳腺癌的疗效及不良反应。方法将51例晚期乳腺癌患者随机分成2组,其中采用TP方案治疗组26例,采用NP方案治疗组25例;TP方案:紫杉醇135mg/m2,静脉滴入,d1,冻干顺铂30mg/m2,静脉滴入,d1-3;NP方案:长春瑞滨(盖诺)25mg/m2,d1、d6,静脉滴入,d1,冻干顺铂30mg/m2,静脉滴入,d1-d3;上述两个方案每3、4周为1个周期。结果TP方案的总有效率为50%(13/26),中位疾病进展时间(TTP)8.1个月,中位生存时间16个月,1年生存率为59.1%;NP方案的总有效率为40.0%(10/25),中位疾病进展时间(TTP)6.8个月,中位生存时间15.0个月,1年生存率为45.0%。两组方案的主要不良反应为骨髓抑制及胃肠道反应。结论两组方案对于晚期乳腺癌患者均有较好疗效,不良反应可耐受,其近期疗效差异无统计学意义,P>0.05。

Clinical observation of TP and NP regimen in patients with advanced breast cancer

Objective To study the curative effect and adverse drug reactions of TP regiment and NP regiment in treating advanced mammary carcinoma. Method 62 cases of advanced mammary carcinoma patients were divided to two groups randomly. One group included 26 patients treated with TP regiment,and the other group included 25 patients with NP regiment. TP regiment: Paclitaxel 135 mg/m2,by infusion on days 1,Cis-Diaminodichloroplatinum 30 mg/m2,by infusion on days 1,2,3. NP regiment: Vinorelbine Tartrate 25 mg/m2,by infusion on days 1,6,Cis-Diaminodichloroplatinum 30 mg/m2,by infusion on days 1,2,3. Every 3-4 weeks is a cycle in TP regiment and NP regiment. Result For TP regiment: the total effective rate of was 50%( 13/26),TTP is 8.1 months,the median survival time was 16 months,and the rate of survival in one year was 59.1%. For NP regiment: the total effective rate of was 40 %( 10/25),TTP was 6.8 months,the median survival time was 15 months,and the rate of survival in one year is 45%. The main adverse drug reactions of two regiments were restraint of marrow and gastrointestinal reactions. Conclusion These two regiments are significantly effective for advanced mammary carcinoma patients. The recent curative effect has no statistically difference between these two regiments,P >0.05. The patients can endure these adverse drug reactions.